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CD1 proteins are expressed together with 2-
microglobulin on the surface of B cells, myeloid 
DCs, Langerhans cells, and other APCs, where 
they capture and display lipid antigens to T cells. 
The  types  of  lipid  antigens  presented  by  the 
CD1 system represent many classes of lipids that 
are biosynthetic products of mammalian cells or 
bacteria, including diacylglycerols (1–4), sphin-
golipids (5, 6), polyisoprenols (7), polyketides 
(8), mycolic acid dervatives (9–11), sulfoglyco-
lipids (12), and other antigens (13). Most of these 
antigens are glycolipids that insert their aliphatic 
hydrocarbon chains into the hydrophobic groove 
of  CD1  so  that  the  carbohydrate  moieties 
protrude from the groove, making them avail-
able for direct contact with TCRs (14–18). 
A recent ternary crystal structure of an  TCR 
bound to a CD1d–-galactosyl ceramide com-
plex shows how the variable regions of the TCR 
contact a galactose moiety lying on the surface 
of CD1d (19). Although T cells had previously 
been thought to recognize mainly linear primary 
amino acid sequences, these studies show how 
T cells with rearranged  TCRs can also dis-
criminate the structure of carbohydrate rings.
However, the larger family of CD1 antigen–
presenting molecules (CD1a, CD1b, CD1c, and 
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The recent discovery of dideoxymycobactin (DDM) as a ligand for CD1a demonstrates how 
a nonribosomal lipopeptide antigen is presented to T cells. DDM contains an unusual 
acylation motif and a peptide sequence present only in mycobacteria, but its discovery 
raises the possibility that ribosomally produced viral or mammalian proteins that com-
monly undergo lipidation might also function as antigens. To test this, we measured T cell 
responses to synthetic acylpeptides that mimic lipoproteins produced by cells and viruses. 
CD1c presented an N-acyl glycine dodecamer peptide (lipo-12) to human T cells, and the 
response was specific for the acyl linkage as well as the peptide length and sequence. 
Thus, CD1c represents the second member of the CD1 family to present lipopeptides. 
lipo-12 was efficiently recognized when presented by intact cells, and unlike DDM, it was 
inactivated by proteases and augmented by protease inhibitors. Although lysosomes often 
promote antigen presentation by CD1, rerouting CD1c to lysosomes by mutating CD1 tail 
sequences caused reduction in lipo-12 presentation. Thus, although certain antigens 
require antigen processing in lysosomes, others are destroyed there, providing a hypoth-
esis for the evolutionary conservation of large CD1 families containing isoforms that 
survey early endosomal pathways.
© 2009 Van Rhijn et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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Although antigen screens initially focused on CD1a because 
it is the only protein known to present a lipopeptide, we unex-
pectedly found that cellular CD1c proteins presented an N-ter-
minal acylated glycine dodecamer peptide to T cells, which we 
designate lipo-12. This antigen mimics structures of proteins 
made through cellular myristoylation of proteins. We found 
that intact APCs deactivated antigen recognition in a process 
that involved peptidases. This discovery raised questions about 
how endosomal peptidases, which are known to control MHC-
restricted peptide recognition, might also control CD1 and li-
popeptide  antigen  complex  recognition.  Functional  studies 
provided evidence for two means by which antigens can be 
protected from degradation in late endosomes or lysosomes. 
First, DDM provides an example of evolution of atypical, pep-
tidase-insensitive linkages that allow it to persist in infected en-
dosomes. Second, the escape of CD1a and CD1c from early 
endosomes to the surface allows peptidase-sensitive antigens to 
avoid exposure to the activated proteases in lysosomes. Most 
models of endosomal lipid antigen processing emphasize the 
sequential passage of CD1 through early and late endosomal 
compartments en route to the cell surface. In contrast, these re-
sults point to a model whereby the ability of CD1c to exit the 
endosomal pathway, before traversing lysosomes, improves an-
tigen recognition. Although recent studies of CD1b and CD1d 
emphasize the importance of lysosomal factors in promoting 
lipid presentation, these results may explain why most mam-
malian species have evolved large families of CD1, including 
those that do not efficiently enter lysosomes.
RESULTS
CD1c presents a lipopeptide to T cells
To determine whether T cells can respond to acylated peptide 
sequences, we synthesized pools of peptides that were modi-
fied on N-terminal glycine, internal cysteine, or internal ly-
sine moieties to mimic structures produced by myristoylation, 
thioacylatoin, or lysine acylation pathways (Fig. S1). These 
candidate antigens were synthesized using standard solid-phase 
peptide synthesis techniques, followed by acylation with satu-
rated (C16:0 and C18:0) or unsaturated (C18:1) fatty acids. 
After purification by HPLC, mass spectrometry (MS) analysis 
demonstrated that products were of the expected mass (Fig. S1 
and not depicted). After stimulating human T cells with ac-
ylpeptides, we screened human T cells from patients with or 
without viral infection for responses to acylpeptide-pulsed, 
monocyte-derived DCs. One of the resulting T cell lines (1A3) 
was found to respond to an N-acylated lipopeptide mixture 
when presented by DCs expressing all five human CD1 pro-
teins (unpublished data).
Because CD1a is the only CD1 isoform previously known 
to bind or present a lipopeptide, testing for the cell-surface 
molecule that mediates the response focused on the use of 
anti-CD1a blocking antibodies. Unexpectedly, we found that 
activation was blocked by anti-CD1c antibodies but not by 
anti-CD1a, -CD1b, or -CD1d (Fig. 1 A). Further studies 
using lymphoblastoid cells transfected with any of the four 
human CD1 antigen-presenting proteins confirmed that T 
CD1d) presents not only antigens with head groups that are 
sugars, but also antigens that are composed of free fatty acids 
(10), polyaromatic hydrocarbons (13), hydrophobic peptides 
(20), and a lipopeptide. The only known lipopeptide antigen 
is a mycobacterial product that binds to CD1a and is named 
dideoxymycobactin (DDM) (21). The crystal structure of hu-
man CD1a bound to a DDM analogue shows that its single 
acyl group is inserted into the groove of CD1a. Its peptide 
chain, composed of four amino acids and two organic acids, 
protrudes from the groove such that the termini of the peptide 
are available to contact TCRs (22). These studies provide 
proof of principle that a CD1 protein, like MHC proteins, can 
present a peptide sequence to T cells. However, it is currently 
unclear whether the range of CD1-presented peptide antigens 
is limited only to this unusual and invariant mycobacterial se-
quence. We hypothesized that lipopeptide recognition by  
T cells might involve any of the multitude of structurally 
varied self- or viral proteins that are encoded in DNA, assem-
bled by ribosomes, and posttranslationally lipidated (23).
In considering the possible diversity of CD1-presented li-
popeptides, there are relevant evolutionary and biochemical 
differences between ribosomal and nonribosomal peptide 
synthesis pathways. DDM is made by the sequential action of 
enzymes known as mycobactin synthases (24). The result-
ing peptide is invariant in sequence. However, the chemical 
linkages are diverse and include esters, oxazaline rings, and 
amide bonds. In contrast, ribosomal translation of peptides 
produces a nearly infinite diversity of peptide sequences by 
linking each of the 20 standard amino acids by repeated am-
ide (peptidic) bonds. Such peptide sequences are then modi-
fied in a limited number of ways on glycine, lysine, or cysteine 
side chains by enzymatically mediated processes known as 
thioacylation, lysine acylation, or myristoylation.
According to the crystal structure, the A pocket of CD1a 
accepts the fatty acyl group, and the F pocket can bind either 
a second fatty acyl chain or accept the peptidic moiety of 
DDM (15, 22). Because of the low levels of polymorphism in 
CD1 heavy chains, the F pocket is thought to be invariant in 
structure among individual humans, so it might be specialized 
to bind only this 5-mer peptide of DDM. Alternatively, the F 
pocket of CD1a or other CD1 isoforms instead might bind 
to structurally diverse molecules, as suggested by the ability of 
CD1a to present sulfolipids using a mechanism whereby an 
alkane chain resides in the F pocket (15, 25). Ribosomally 
encoded peptides are highly diverse and, therefore, potentially 
represent a more general immune recognition pathway that 
could involve any peptide that contains a myristoylation, thio-
acylation, or prenylation site. Toll-like receptor 2-1 heterodi-
mers recognize N-terminal cysteine-based triacylation motifs 
on peptides, but there is currently no evidence that acylated 
proteins are the targets of T cell responses (26, 27). As a first 
step toward testing this general hypothesis, we prepared sev-
eral synthetic lipopeptides that mimic acylated sequences con-
tained within larger proteins produced by mammalian cells 
(IL-1) or viruses (HIV and EBV), and carry an acyl group on 
the N-terminal glycine or cysteine or internal lysine residues.JEM VOL. 206, June 8, 2009 
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Identification of the antigen as an N-terminally acylated 
12-mer peptide
To identify the precise structure of the lipopeptide antigen, the 
mixture of synthetic compounds was fractionated by prepara-
tive HPLC with a split interface to allow for simultaneous 
monitoring by UV absorbance and electrospray ionization MS 
(ESI-MS) and collection of samples for T cell assays. Three 
major lipopeptides were detected at 26, 27, and 29 min of elu-
tion time (Fig. 1 C) and were initially named lipopeptide 1, 2, 
and 3, respectively. Lipopeptides 1 and 3 were detected as dou-
bly charged species at mass-to-charge (m/z) 867.4 and 868.5, 
corresponding to monoisotopic molecular weights of 1,732.8 
and 1,735 u, respectively. Lipopeptide 2 was observed as a sin-
gly charged species with [M+H]+ at m/z 900.7 u. Testing of 
the purified compounds found that only lipopeptides 1 and 3 
stimulated a T cell response, with lipopeptide 3 being approx-
imately fivefold more potent on a molar basis (Fig. 1 D).
To assign the compositions and elucidate the structures   
of the antigenic lipopeptides, we performed collision-induced 
dissociation MS using quadrupole ion trapping (QIT; Fig. 2 
and Fig. S3) and Fourier transform ion cyclotron resonance 
(FTICR) MS (Table I). In the QIT MS2 spectrum for lipo-
peptide 3, the [M+2H]2+ of m/z 1,735 generated product ions 
that constitute a series of peptide sequence–related fragments at 
m/z 1,316.8, 1,502.9, and 1,589.9. These ions correspond to 
the b9, b10, and b11 fragments of a C-terminal sequence, WSK 
cell activation was dependent on lipopeptide dose and abso-
lutely dependent on expression of CD1c on APCs (Fig. 1 B). 
Last, we found that 1A3 T cells did not cross react with other 
lipopeptides bearing distinct sequences and lysine acylation 
and thioacylation modifications, demonstrating specificity of 
the T cell response for the pool of N-terminal glycine acyla-
tion products (Fig. S1).
We next determined the TCR variable segments of the T 
cell clone by PCR using a set of primers that covered most 
known TCR human variable segments. This analysis repro-
ducibly led to a strongly positive PCR signal for the TRBV12-3 
segment, used in the  chain, but products obtained with 
TRAV segment–specific primers were not observed (unpub-
lished data). Because the PCR primer sets do not cover all 
possible variable segments, we performed inverse PCR on 
circularized cDNA primed with TCR  and  constant re-
gion primers, followed by cloning and sequencing of the 
PCR product. This method confirmed that the TRBV12-3 
segment was present and identified the TCR  chain as 
containing TRAV25. Determination of the complete se-
quences of the 1A3 TCR  and  chains (available from 
GenBank/EMBL/DDBJ under accession nos. EU599571 and 
EU599572) confirmed that they were distinct from the TCR 
 and  chains of previously reported CD1c-restricted T cell 
lines (28, 29), and different from the V24 chains that define 
invariant CD1d-restricted NK T cells (Fig. S2).
Figure 1.  CD1c presents lipopeptide antigens to T cells. (A) [3H]Thymidine incorporation by the IL-2–sensitive HT-2 cell line was used to measure the 
response of polyclonal 1A3 T cells stimulated with DC and antigen. mAbs against CD1a, CD1b, CD1c, CD1d, or isotype-matched control were added at  
20 µg/ml before adding antigen mixture at 0.5 µg/ml. This experiment was performed twice. (B) CD1-deficient C1R B lymphoblastoid cells transfected with 
cDNAs encoding human CD1a, CD1b, CD1c, CD1d, or no insert (mock) were treated with the antigen mixture before adding polyclonal 1A3 T cells and mea-
suring IL-2 release. This experiment was performed twice. (C) Three major compounds were purified from a mixture of synthetic lipopeptide antigens using 
an effluent flow splitter on an HPLC interfaced to an ESI-MS. Total ion current is the basis for the relative abundance that is plotted on the y axis, and posi-
tive mode spectra corresponding to the time interval of each peak are shown. (D) The amount of each of the three major compounds was normalized for 
absorbance at 280 nm and used to stimulate 5 × 104 1A3 T cells with 3 × 104 DC, as measured by [3H]thymidine incorporation. Error bars represent SEM.1412 PRESENTATION OF LIPOPEPTIDES BY CD1C | Van Rhijn et al.
structure of lipopeptide 3 was assigned as C18:0-GGKWSKX-
SKWSK, where X is kynurenine with ester linkage (Fig. 2 A).
This conclusion is supported in more detail and with higher 
mass resolution by the FTICR MS, which includes the series 
b3–b6 and b8–b11 and their secondary fragments that arise via 
loss of the acyl moiety as the corresponding ketene (CHRCO, 
R = C14H29 or C16H33), as well as the y9, y10, and y11 fragments 
(Fig. 2 B). MS3 analysis of the product ion at m/z 928.6 was 
consistent with an N-stearoyl hexapeptide with the amino 
acid sequence GGKWSK and a C-terminal hydroxyl terminus   
(Fig. 2 B, bottom). Formation of this fragment is best ratio-
nalized by the elimination of a peptide with kynurenine, an 
oxidized form of tryptophan, at its N terminus that had been 
released from an ester linkage to lysine at position six. Thus, the 
Figure 2.  Mass spectrometric analysis identifies antigens as acylated 12-mer peptides. (A) The three major components eluting in LC-MS ex-
periments were named according to their HPLC elution times as lipopeptide 1, 2, or 3. The structures were deduced on the basis of low- and high-reso-
lution MS and MSn experiments. X corresponds to a mass shift consistent with O-linked kynurenine, likely resulting from oxidation of tryptophan during 
the synthesis process. (B) QIT MS2 and MS3 data support the structure of lipopeptide 3. Assignments were also based on the accurate mass values mea-
sured by FTICR MS analyses that are presented in Table I. The b9–11 ion series at m/z 1,316.8, 1,502.9, and 1,589.9 corresponds to N-terminal fragments 
that provide the sequence WSK. The y9 ion at m/z 1,227.6 and its water loss peak at m/z 1,209.5 are consistent with the sequence C18:0-(GGK)[1,227.6] 
that is more fully defined by the MS3 spectrum shown in the inset. Internal ions that bracket the O-Kyn residue (am/zn and bmyn) are also present, as 
indicated by assignments on the MS2 spectrum. The presence of an ester linkage in the peptide backbone is confirmed by the MS3 spectrum obtained 
after isolation and decomposition of the c6 fragment ion at m/z 928.6. In the MS3 spectrum, the b-type fragments at m/z 509, 695, 782, and 910 indi-
cate the sequence WSK and the presence of an ester-derived C-terminal -OH rather than the -NH2 that would have resulted from N-C cleavage of an 
amide linkage. In addition, y-type fragments observed at m/z 420, 548, and 605 define the N terminus as C18:0-GGK. Spectra obtained during compa-
rable experiments leading to the deduced structures of lipopeptides 1 and 2 are shown in Fig. S2, and the corresponding FTICR MS accurate mass as-
signments are listed in Table I. (C) Secretion of IL-2 by 1A3 T cells was measured in response to lipopeptide 3 (C18-GGKWSKXSKWSK) or synthetic 
analogues generated with C18 fatty acids carried on the N-terminal glycine or isoleucine residues presented by DCs. (D) ELISPOT detection of IFN- 
capture in response to DCs treated with lipopeptide 3 or an analogue containing tryptophan in place of kynurenine (C18-GGKWSKWSKWSK). This ex-
periment was performed three times with essentially the same results. *, >1,500 spots per well. (E) Recombinant CD1c-Ig fusion proteins were bound to 
a protein G–coated plate and treated with the indicated lipopeptide in molar excess before MPM antigen was added. After washing, the MPM-specific, 
CD1c-restricted T cell line CD8-1 was added and IFN- release was measured by ELISA. One out of three independently performed experiments is shown. 
Error bars represent SEM.JEM VOL. 206, June 8, 2009 
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To determine whether these lipopeptides interact with 
CD1c, we measured their ability to compete against a known 
CD1c antigen, mannosyl phosphomycoketide (MPM), for 
presentation by recombinant CD1c proteins. Based on a con-
struct for a CD1d-Ig fusion protein (2), we produced CD1c-
Ig fusion protein, bound it to plastic, treated it with MPM, 
and washed before adding MPM-reactive T cells. MPM-
treated  CD1c  proteins  activated  the  MPM-reactive  line 
CD8-1 to release IFN- at high levels, providing evidence 
that the response requires MPM contact with CD1c (7, 30). 
Lipopeptide antigens did not activate CD8-1 (not depicted) 
but could completely inhibit the response to CD1c-MPM 
(Fig. 2 E). Specifically, lipo-12, as well as the tryptophan 
point mutant, can effectively diminish the presentation of 
MPM, albeit at different molar ratios. In contrast, the nonac-
ylated form of the tryptophan mutant does not inhibit T cell 
response at any of the molar ratios tested. We conclude from 
these experiments that the acyl modification of the lipopep-
tides is necessary for binding of lipopeptides to CD1c, and 
that the difference in potency between lipo-12 and its tryp-
tophan mutant is mainly caused by altered recognition by the 
1A3 TCR.
Antigenic glycine-1–acylpeptides are sensitive  
to protease degradation
The loading of exogenous antigens by CD1 proteins occurs 
within the endosomal network of APCs. This process re-
quires that antigens are taken up by phagocytosis or receptor-
mediated endocytosis, and that CD1 proteins are transported 
from the surface to endosomes after sorting interactions me-
diated by clathrin adaptor protein (AP) complexes (31–36). 
Although human CD1a proteins transit endosomes less ex-
tensively than other isoforms, they do reach sorting endo-
somes and can present lipids from intracellular infection (32, 
37, 38). CD1c proteins recycle to endosomes based on the 
interactions of their cytoplasmic tail sequences with the AP-2 
complex, but they enter lysosomes and localized with lyso-
some association membrane protein 1 (LAMP1) only at very 
low levels compared with human CD1b and mouse CD1d 
(34, 35, 39). These endosomally localized loading reactions 
serve to concentrate antigens, lower pH, and provide load-
ing  cofactors  that  promote  presentation  of  lipid  antigens 
other than those studied in this paper. However, endosomal 
antigen processing necessarily exposes both CD1 and anti-
gens to endosomal proteases, so the discovery of CD1 anti-
gens that contain peptide sequences raises questions about 
how endosomal proteases may generate or even destroy 
antigenic lipopeptides. Therefore, we undertook studies to 
measure the influence of defined proteases and natural pro-
teolytic compartments on lipopeptide antigen recognition 
by T cells.
When the CD1a-presented, 6-mer lipopeptide DDM was 
pretreated with either of two broad spectrum proteases, pro-
teinase K and pronase, it retained its ability to stimulate T 
cells at the same level as mock-treated samples (Fig. 3 A). In 
contrast, pronase and proteinase K nearly abolished recognition 
accompanied by water loss peaks from all of these and from the 
y6 ion. Internal fragment ions that include the modified, ester-
linked tryptophan residue (W*) are also plentiful (Table I).
An analogous interpretation of both FTICR and QIT 
spectra from lipopeptide 1 indicates that it is the same pep-
tide as found in lipopeptide 3, except that the Gly1 of lipo-
peptide 1 is acylated with C18:1 rather than C18:0 (Fig. S3). 
This interpretation is in agreement with the synthesis scheme 
in which C18:0 and C18:1 fatty acids were included in the 
mixture used to generate the lipopeptides. The fivefold lower 
potency of lipopeptide 1 (Fig. 1 D) correlates with the pres-
ence of an unsaturation in its fattyl acyl chain, indicating that 
the lipidic portion of the molecule strongly influences its an-
tigenicity. More generally, we conclude that CD1c can be 
considered the second member of the CD1 family that has 
been shown to present a lipopeptide to T cells. It is notewor-
thy that the position, amino acid residue, and chemical link-
age of the fatty acyl substituent on this synthetic lipopeptide 
are chemically identical to that formed in N-terminal glycine 
acylation reactions (myristoylation) in mammalian cells.
Lipid, peptide, and linkage specificity of the T cell response
After solving the complete structures of lipopeptides 1, 2, and 
3, we next determined T cell specificity for analogues that 
differed in the lipid saturation, peptide length, and peptide se-
quence using additional synthetic lipopeptide analogues that 
were purified and analyzed by HPLC-MS (Figs. S4 and S5). 
Lipopeptide 2 was similar to the core structure of lipopeptide 
3, except for a small difference in lipid length and that six resi-
dues of its C terminus were absent. Therefore, the failure of T 
cells to recognize lipopeptide 2 likely indicated that the longer 
peptide was required for recognition. The terminal amino ac-
ids may have contributed to recognition in some general way, 
such as promoting solubility, or represent an amino acid se-
quence–specific recognition event. To directly test this hy-
pothesis, we generated a lipopeptide that retains the acyl unit 
and overall 12-mer length but differs from lipo-12 (C18-GG-
KWSKXSKWSK) in its C-terminal sequence (C18-GGK-
WSKSSIVGW; Fig. S4). Also, we produced a point mutant at 
position 7 in which kynurenine is substituted with tryptophan 
(C18-GGKWSKWSKWSK) along with the nonacylated ver-
sion (Fig. S5). T cells did not detectably respond to the multi-
ply substituted 12-mer lipopeptide or the isoleucine-acylated 
analogue, demonstrating the importance of N- and C-terminal 
elements of sequence in the response (Fig. 2 C).
Interestingly, the tryptophan point mutant was recognized 
in a dose-dependent manner, albeit at a lower titer when tested 
in sensitive single-cell cytokine capture ELISA (ELISPOT) as-
say (Fig. 2 D). This result provides evidence from a second, 
independently synthesized molecule that 12-mer lipopeptides 
can activate T cells. We conclude that a single point mutation 
strongly influences the potency of the response, but kynuren-
ine is not absolutely required. Further, testing of the nonacyl-
ated peptide (GGKWSKWSKWSK) produced no detectable 
response (Fig. S5 and not depicted), further emphasizing the 
role of the acyl group in recognition.1414 PRESENTATION OF LIPOPEPTIDES BY CD1C | Van Rhijn et al.
Table I.  Exact mass of ions and product ions in lipo-12 as determined by FTICR-MS
Obs.  
m/z
z [M+H]+ Abd. Calc.  
m/z
Assignment Error Obs.  
m/z
z [M+H]+ Abd. Calc.  
m/z
Assignment Error
  (%) (ppm) (%) (ppm)
579.342 3 1,736.011 33.4 1,736.015 [M+H]+(C18:0) 2.2 1,188.689 1 1,188.689 2.7 1,188.703 b8(C18:0) 11.8
868.507 2 1,736.007 6.5 1,736.015 [M+H]+(C18:0) 4.8 1,186.675 1 1,186.675 0.7 1,186.687 b8(C18:1) 10.2
578.671 3 1,733.998 14.2 1,733.999 [M+H]+(C18:1) 0.6 590.302 2 1,179.597 1.1 1,179.595 b10y11 1.3
867.501 2 1,733.993 5.8 1,733.999 [M+H]+(C18:1) 3.5 1,179.586 1 1,179.586 1.2 1,179.595 b10y11 7.7
573.34 3 1,718.003 11 1,718.005 [M+H-H2O]+(C18:0) 1.1 1,170.691 1 1,170.691 1.1 1,170.693 b8-H2O(C18:0) 1.5
859.505 2 1,718.001 2.7 1,718.005 [M+H-H2O]+(C18:0) 1.9 1,161.587 1 1,161.587 0.9 1,161.585 b10y11-H2O 1.8
572.669 3 1,715.99 4.1 1,715.989 [M+H-H2O]+(C18:1) 0.9 1,099.519 1 1,099.519 6.5 1,099.521 b11y9+H2O 2.1
858.496 2 1,715.985 1.1 1,715.989 [M+H-H2O]+(C18:1) 2.5 1,081.509 1 1,081.509 9.9 1,081.511 b11y9 1.6
854.494 2 1,707.98 1 1,707.984 [M+H]+(C16:0) 2.3 1,063.497 1 1,063.497 2.5 1,063.5 b11y9-H2O 2.9
804.462 2 1,607.916 9.5 1,607.92 b11+H2O(C18:0) 2.8 1,050.534 1 1,050.534 7.6 1,050.537 b9-CHRCO 3
803.455 2 1,605.903 7.1 1,605.904 b11+H2O(C18:1) 0.9 1,032.522 1 1,032.522 0.7 1,032.527 b9-CHRCO-H2O 4.5
795.457 2 1,589.907 7.3 1,589.91 b11(C18:0) 1.7 994.478 1 994.478 3.9 994.479 b10y9 0.7
794.451 2 1,587.894 2.7 1,587.894 b11(C18:1) 0.1 993.515 1 993.515 3.6 993.516 b9y11 0.8
786.453 2 1,571.898 1 1,571.899 b11-H2O(C18:0) 0.6 976.465 1 976.465 1.7 976.468 b10y9-H2O 3.2
751.941 2 1,502.873 4.6 1,502.878 b10(C18:0) 2.9 475.234 2 949.46 1 949.457 a10z9 3.3
750.934 2 1,500.861 1.9 1,500.862 b10(C18:1) 0.8 949.457 1 949.457 20.1 949.457 a10z9 0
742.937 2 1,484.867 2.5 1,484.867 b10-H2O(C18:0) 0.1 928.621 1 928.621 100 928.624 c6(C18:0) 2.8
741.93 2 1,482.852 1 1,482.851 b10-H2O(C18:1) 0.6 926.605 1 926.605 37.3 926.608 c6(C18:1) 3.1
735.38 2 1,469.753 22.1 1,469.754 [M+H-CHRCO]+ 0.6 922.44 1 922.44 1.6 922.442 b8-CHRCO 2.2
490.591 3 1,469.756 1.4 1,469.754 [M+H-CHRCO]+ 1.4 910.611 1 910.611 6.7 910.613 b6(C18:0) 2.2
726.375 2 1,451.742 8.3 1,451.744 [M+H-CHRCO-  
H2O]+
1.2 908.594 1 908.594 1.6 908.597 b6(C18:1) 3.7
717.37 2 1,433.732 1.1 1,433.733 [M+H-CHRCO-  
2H2O]+
0.9 900.592 1 900.592 15.4 900.592 [M+H]+6mer(C16:0) 0.3
706.87 2 1,412.732 12.7 1,412.733 y11 0.6 882.579 1 882.579 0.8 882.581 [M+H-H2O]+  
    6mer(C16:0)
2.1
697.865 2 1,394.723 5.7 1,394.722 y11-H2O 0.6 865.42 1 865.42 2.6 865.421 b8y11 0.9
688.86 2 1,376.712 0.9 1,376.712 y11-2H2O 0 847.409 1 847.409 1.2 847.41 b8y11-H2O 1.5
678.36 2 1,355.711 0.9 1,355.711 y10 0.1 404.704 2 808.4 2.5 808.399 y6-H2O(#) 1
671.333 2 1,341.659 1.7 1,341.659 b11-CHRCO+H2O 0.1 808.398 1 808.398 9.8 808.399 y6-H2O(#) 1.7
669.354 2 1,337.701 0.7 1,337.701 y10-H2O 0.3 806.382 1 806.382 1.7 806.383 y6-2H-H2O(#) 1.2
662.329 2 1,323.649 3.2 1,323.649 b11-CHRCO 0.6 790.388 1 790.388 1.1 790.389 y6-2H2O(#) 1
1,316.803 1 1,316.803 3.2 1,316.798 b9(C18:0) 3.5 782.517 1 782.517 2.3 782.518 b5(C18:0) 1.3
658.903 2 1,316.798 3.9 1,316.798 b9(C18:0) 0.2 780.501 1 780.501 0.7 780.502 b5(C18:1) 2.1
1,314.787 1 1,314.787 1.1 1,314.783 b9(C18:1) 3.7 695.485 1 695.485 3.1 695.486 b4(C18:0) 1.4
657.896 2 1,314.784 1.3 1,314.783 b9(C18:1) 0.9 693.471 1 693.471 1 693.47 b4(C18:1) 0.3
653.323 2 1,305.638 0.8 1,305.638 b11-CHRCO-H2O 0.4 680.304 1 680.304 6.6 680.304 b8y9 0.1
633.817 2 1,266.626 2.1 1,266.627 b11y11 1.1 677.475 1 677.475 1.7 677.475 b4-H2O(C18:0) 0.6
618.813 2 1,236.617 2.3 1,236.617 b10-CHRCO 0.6 675.46 1 675.46 0.6 675.46 b4-H2O(C18:1) 0.1
1,236.618 1 1,236.618 1.4 1,236.617 b10-CHRCO 1.2 662.363 1 662.363 1.6 662.363 b6-CHRCO+H2O 0.7
614.311 2 1,227.615 6.1 1,227.616 y9 1 662.294 1 662.294 5.2 662.294 b8y9-H2O(#) 0.3
1,227.62 1 1,227.62 1.9 1,227.616 y9 3.1 644.283 1 644.283 2.4 644.283 b8y9-2H2O(#) 0.5
1,218.61 1 1,218.61 1.1 1,218.606 b10-CHRCO-H2O 3.3 634.298 1 634.298 1.1 634.299 a8y9-H2O(#) 1.4
609.807 2 1,218.607 1.4 1,218.606 b10-CHRCO-H2O 0.5 575.262 1 575.262 4.1 575.262 b7y9-H2O(#) 0.3
605.306 2 1,209.605 2.2 1,209.606 y9-H2O(#) 0.7 547.267 1 547.267 6.1 547.267 a7y9-H2O 0.2
1,209.607 1 1,209.607 1.4 1,209.606 y9-H2O(#) 1.1 530.241 1 530.241 3.6 530.241 a7z9-H2O 0
1,205.728 1 1,205.728 2.2 1,205.73 c8(C18:0) 1.5 491.396 1 491.396 1 491.396 b3-H2O(C18:0) 0.4
1,203.711 1 1,203.711 0.7 1,203.714 c8(C18:1) 2.4 420.225 1 420.225 1.7 420.225 y3(#) 0.7JEM VOL. 206, June 8, 2009 
ARTICLE
1415
Redirection of CD1c trafficking to lysosomes reduces  
lipo-12 presentation
Proteinase K, pronase, and the targets of inhibition by LHVS 
may not produce the same effects as the more complex array 
of endogenous proteases normally present in the endosomal 
network. To test the role of naturally occurring endosomal 
factors in lipopeptide presentation, we devised a means to re-
route CD1c trafficking from its normal steady-state location 
in early endosomes so that it more efficiently reaches late en-
dosomal and lysosomal compartments. AP-3 complexes lo-
calize broadly within the endosomal pathway and promote 
directed trafficking of cargo proteins to lysosomes (42). Pre-
vious studies had shown that the cytoplasmic tail sequence 
in CD1c (KKHCSYQDIL) binds to AP-2 but not AP-3 
(32, 35). In contrast, the cytoplasmic tail sequence in CD1b 
(RRRSYQNIP) binds to both AP-2 and AP-3. Therefore, 
to reroute the antigen binding domain of CD1c to lysosomes, 
we produced a construct encoding a chimeric protein with 
CD1c extracellular and transmembrane domains fused to the 
CD1b cytoplasmic tail sequence (CD1cextra/CD1btail).
To facilitate visualization by two-color immunofluores-
cence,  we  cotransfected  a  plasmid  encoding  this  chimera 
along with one encoding wild-type CD1b into C1R B lym-
phoblastoid cells. As a control, we produced a construct en-
coding the converse chimera with CD1b extracellular and 
of the N-terminal N-acyl lipopeptide antigen presented by 
CD1c (Fig. 3 B). The reduced T cell activation after protease 
treatment was likely caused by action on the 12-mer lipopep-
tides rather than nonspecific or toxic effects on cells, because 
adding fresh lipo-12 to the protease–antigen mixture after 
protease inactivation restored T cell responses (Fig. 3 C). There-
fore, we conclude that DDM has intrinsic resistance to broad-
spectrum  proteases  but  the  12-mer  lipopeptides,  which 
contain typical peptide bonds, were inactivated.
We next considered whether the naturally occurring pro-
teases, which are normally expressed within endosomes of B 
cells or immature myeloid DCs, might also influence lipo-
peptide recognition. First, we treated DCs with the endopro-
tease inhibitor LHVS, an inhibitor of the lysosomal protease 
cathepsin S (40, 41). We reproducibly found two- to fourfold 
increases in the presentation of lipo-12 (Fig. 3 D). Although 
the augmentation in recognition was relatively small in mag-
nitude, it was considered to be important because LHVS does 
not block all types of endoproteases and also because any 
nonspecific effects of protease inhibitors would be expected 
to reduce rather than to augment recognition. This result in-
dicated that endosomal endoproteases can degrade this antigen 
and raised questions about how proteases distributed among 
the diverse subcompartments of the endosomal pathway might 
influence recognition.
Table I.  Exact mass of ions and product ions in lipo-12 as determined by FTICR-MS (Continued)
Columns reflect the observed m/s (Obs. m/z), charge number of the ion (z), mass of the singly protonated molecular ion [M+H], abundance of the ion expressed as a 
percentage of the strongest ion (Abd.), calculated mass of the singly protonated ion (Calc. m/z), and assignment of the ion and the error of the observed mass relative to the 
calculated mass expressed as parts per million (Error). (#), redundant composition; R in CHRCO, acyl moiety as ketene (C14H29 or C16H33).
Figure 3.  Proteases influence recognition of lipopeptides. (A and B) lipo-12 and DDM were treated with proteinase K or pronase, or were mock 
treated in the same buffer without the proteases, and were used to stimulate 1A3 T cells and CD1a-restricted J.RT3/CD8-2 cells, respectively. Error bars 
represent SEM. (C) To test whether protease-treated lipo-12 itself or the inactivated proteases present in the digestion mixture were toxic to 1A3 T cells, 
high concentrations (10 µg/ml) of these mixtures were tested in the presence of a suboptimal amount of untreated lipo-12. (D) lipo-12 was added to DCs 
in the continuous absence or presence of 10 ng/ml of the protease inhibitor LHVS, and proliferation of 1A3 T cells was measured. This experiment was 
performed twice with essentially the same result.1416 PRESENTATION OF LIPOPEPTIDES BY CD1C | Van Rhijn et al.
transmembrane domains fused to the CD1c cytoplasmic tail 
(CD1bextra/CD1ctail) and coexpressed this with wild-type 
CD1c proteins. Confocal immunofluorescence studies were 
then performed using antibodies specific for the extracellular 
domains of CD1b or CD1c. For wild-type CD1c, we found 
that antibodies recognizing the extracellular domain stained 
predominantly at the rim of lymphoblastoid cells, which is a 
pattern consistent with the known distribution of CD1c at 
the cell surface and early endosomes. In contrast, antibodies 
against the extracellular domain of CD1b stained with a rim 
pattern as well as at many punctuate bodies located adjacent 
to the rim, which likely represented late endosomes (Fig. 4, 
top row). This interpretation is in agreement with previous 
studies performed in myeloid cells and HeLa cells showing 
that the cytoplasmic tail of CD1b confers efficient trafficking 
from the surface to endosomes and a higher endosomal-to-
cell surface ratio than is seen for CD1c (31, 34). Using anti-
CD1c to evaluate the staining pattern of the CD1cextra/CD1btail 
chimera, we found that the chimera had clear increases in 
the nonrim, punctate staining as compared with wild-type 
CD1c (Fig. 4 A, left column). In fact, the chimera strongly 
colocalized  with  coexpressed  CD1b  wild-type  proteins, 
demonstrating that the chimeric CD1c protein was rerouted 
to compartments normally enriched with CD1b (Fig. 4 A, 
bottom row). Conversely, the CD1bextra/CD1ctail chimera 
lost the punctate staining pattern and appeared mainly at the 
rim of cells (Fig. 4 A, middle row).
To better visualize the compartments and compare CD1c 
and CD1cextra/CD1btail steady-state localization in lysosomes, 
we performed higher resolution confocal studies in comparison 
to LAMP1. We analyzed stably expressing clones that were 
matched for equivalent levels of surface anti-CD1c staining in 
flow cytometry. As predicted by previous studies (31, 32, 34, 
35), we observed a higher ratio of punctate-to-rim staining in 
the chimeric protein, suggesting redistribution from the surface 
to endosomes. More importantly, addition of the CD1b tail to 
the antigen binding domain of CD1c causes much stronger co-
localization with LAMP1, indicating that this mutation drives 
the antigen binding domain of CD1c into lysosomes Fig. 4 B. 
Therefore, chimeric CD1c proteins represent a tool to measure 
lysosomal effects on lipopeptide antigen presentation.
To  measure  antigen  presentation,  we  used  transfected 
C1R clones with equivalent cell-surface levels of wild-type 
or chimeric CD1c (Fig. 4 C, right). T cell stimulation assays 
showed that chimeric proteins were 5- to 10-fold less effi-
cient in presenting lipo-12. This was not caused by a general 
loss of antigen-presenting capacity of the C1R clone or the 
mutant CD1c protein because MPM, a glycolipid that is not 
Figure 4.  Redirected trafficking of CD1c to lysosomes reduces lipo-
peptide antigen presentation. (A) To enable side-by-side comparison of 
expression patterns of wild-type and chimeric proteins, C1R lympoblastoid 
cells were doubly transfected with cDNAs as indicated, permeabilized, and 
stained with an antibody against the extracellular part of CD1b (BCD1b.3; 
blue) or CD1c (F10/21A3.1; red) Pseudocolored confocal laser scanning 
microscopy images are shown. Bar, 10 µm. (B) Colocalization of CD1c wild-
type or CD1cextra/CD1btail with LAMP1 was studied using directly labeled 
antibodies against the extracellular part of CD1c (F10/21A3.1; red) and 
LAMP1 (H4A3; transformed into green) antibodies. Colocalization of CD1c 
and LAMP1 is shown (yellow). Bar, 10 µm. Insets show a higher magnifica-
tion of a single cell. (C) Stably transfected C1R cells were cloned, and indi-
vidual clones were matched for equivalent surface expression of CD1c 
(white) as compared with an isotype control (gray). The expression of  
CD1cextra/CD1btail is shown with a thin line (MFI 585), and wild-type CD1c is 
shown with a thick line (569 MFI). The C1R transfectants were used to 
present lipo-12 to 1A3 T cells or MPM to CD8-1 T cells. The experiment 
shown is representative of five independently performed experiments.  
(D) C1R cells transfected with CD1b or with mutant CD1b with the cyto-
plasmic tail of CD1c were used to present C80 GMM, C54 GMM, or C32 GMM 
presented to LDN5 T cells. Supernatants were tested for the presence of IL-2 
using the HT-2 bioassay. Error bars represent SEM.
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the phagosomal space while carrying out DDM’s normal iron 
scavenging function.
Although the site of loading of DDM onto CD1a within 
infected cells and tissues has not been formally established, 
infection of intact human DCs with live Mycobacterium tuber-
culosis leads to activation of CD1a-restricted and DDM-spe-
cific T cells (21, 49). Further, CD1a is normally expressed on 
myeloid cells in lepromatous and tuberculous lesions in hu-
mans (50), and CD1a is up-regulated upon mycobacterial in-
fection of immature DCs in vitro (51). These considerations 
and new data shown in this paper suggest a model whereby 
an intrinsically protease-resistant lipopeptide antigen is shed 
from  the  mycobacterial  surface,  traverses  the  phagosomal 
space, and contacts CD1a proteins. Such protease resistance 
derives directly from the nonribosomal nature of DDM bio-
synthesis and evolutionary pressure to function as an iron 
scavenger in a protease-rich compartment. Such consider-
ations do not apply to ribosomally translated proteins con-
taining repeating amide bonds formed between the C and N 
termini of amino acids, as in lipo-12.
The discovery of T cell recognition of the synthetic lipo-
peptide lipo-12 expands the known reactivity of CD1 to in-
clude an N-terminally acylated peptide. This synthetic molecule 
is related in structure to naturally produced lipopeptides made 
through N-terminal glycine acylation (myristoylation) of pro-
teins that are widely distributed in eukaryotic cells and viruses. 
N-terminal N-acyl glycine–modified proteins comprise 0.7%   
of mammalian proteins and 3.5% of viral proteins (http://
mendel.imp.ac.at/myristate/myrbase/). Such acyl proteins par-
ticipate in intercellular signaling (Wnt and integrins), intracellular 
signaling (G proteins and neurotransmitter receptors), cell-cycle 
control (Src family members), and other processes. Also, viral 
genomes encode proteins that are normally acylated, including 
Nef proteins, which are important for viral budding (52).
In contrast to DDM, lipo-12 is sensitive to degradation by 
proteases. This feature is not shared by previously known 
CD1-presented lipid antigens and raises the question of a pos-
sible role of endosomal peptidases in generating or destroying 
epitopes in larger acyl-proteins. Many studies of antigen pro-
cessing by MHC class II found that protein degradation is not 
rapid and not complete during the early phases of uptake into 
macrophages or DCs, but instead occurs in a stepwise fashion 
as proteins transit from sorting to early and late endosomes 
and lysosomes (53–55). Immature myeloid DCs partially pre-
serve peptide structure so that they are cleaved internally but 
not fully destroyed (56). In humans, immature myeloid DCs 
normally express CD1 proteins, so we speculate that this phe-
nomenon may also influence lipopeptide generation and 
production of antigens for the CD1 system. Our studies of 
lipo-12 show that a lipopeptide is composed of conventional 
peptidic linkages and that the peptide sequence determines T 
cell activation. Further, lipo-12 recognition is abolished by 
proteases, enhanced by a cathepsin inhibitor, and reduced af-
ter redirecting CD1c protein trafficking to lysosomes.
Individual members of the human CD1 family (CD1a, 
CD1b, CD1c, and CD1d) differ with regard to the extent 
sensitive to proteases, was presented equally well by wild-
type and mutant CD1c (Fig. 4 C, middle). We conclude that 
rerouting CD1c proteins to later endosomal compartments, 
which are normally used by CD1b, reduces efficiency of pre-
sentation of a lipopeptide antigen.
Further controls using wild-type and chimeric CD1b pro-
teins showed that expression of CD1bextra/CD1ctail provides 
100-fold less efficient presentation of C80 glucose monomy-
colate (GMM) when compared with presentation by wild-
type CD1b proteins. The C80 GMM antigen is a long-chain 
lipid whose loading is known to depend on low pH and, thus, 
to occur more efficiently in late endosomal and lysosomal 
compartments with pH <5.5 (43, 44). The presentation effi-
ciency  loss  resulting  from  expressing  the  CD1b  with  the 
CD1c tail was smaller when tested with C32 and C54 GMM 
antigens, whose loading is less dependent on the low pH of 
lysosomes based on the less stringent requirements for loading 
antigens with smaller lipid tails. Collectively, these additional 
controls provide evidence for two conclusions. First, the pres-
ence or absence of AP-3 interactions and the resulting redi-
rection to either early or late endosomes substantially influences 
the antigen-presenting function of CD1b and CD1c, con-
firming the idea of functional segregation of antigen presenta-
tion  events  into  early  and  late  endosomal  compartments. 
Second, whether redirection increases or decreases the abso-
lute efficiency of presentation depends on the identity of the 
antigen and the extent to which late endosomal and lysomal 
events influence its processing and loading.
DISCUSSION
The discovery of lipo-12 represents a new class of lipopeptide 
antigen presented by CD1 and provides the first evidence 
that CD1c presents lipopeptides to T cells. lipo-12 resembles 
ribosomally  produced  peptides  modified  by  N-myristoyl 
transferase. In fact, the linkage of the N-terminal acylation and 
the first six amino acids are chemically identical to the natu-
rally occurring acylated-Nef sequence produced by HIV-1 
during cellular infection (45). Thus, at least two members of 
the CD1 family (CD1a and CD1c) bind and present lipopep-
tides. Because all human CD1 isoforms (CD1a, CD1b, CD1c, 
CD1d, and CD1e) traffic through endosomal compartments 
containing peptidases, and cathepsin S and cathepsin L have 
been shown to affect CD1d-restricted T cell activation, these 
findings raise questions about how endosomal peptidases 
might interact with CD1-presented antigens composed of 
peptides (46, 47).
The observed inability of even broadly acting peptidases 
to  cleave  DDM  likely  results  from  atypical  (nonpeptidic) 
linkages between individual amino and organic acids, includ-
ing an oxazaline ring and an internal ester. DDM and struc-
turally related mycobactins and carboxymycobactins undergo 
transport to the mycobacterial surface and release into the 
phagosomal space, where they directly interface with the host 
and bind iron for uptake into the mycobacterium (48). These 
unusual chemical linkages among amino acids were likely 
evolutionarily selected for their ability to remain intact within 1418 PRESENTATION OF LIPOPEPTIDES BY CD1C | Van Rhijn et al.
to retain larger numbers of CD1 genes, including CD1 pro-
teins that sample lysosomes and those that do not.
Collectively, the discovery of lipo-12 as a CD1-presented 
antigen for human  T cells and the identification of the 
N-terminal acylation as the key unit that facilitates presentation 
of the antigen by CD1c raise the possibility that other N-termi-
nally acylated peptides, including posttranslationally modified 
products of ribosomal translation, might also be antigens for 
the CD1 system. All previously known CD1-presented anti-
gens are not encoded by a host or pathogen genome, but 
instead are generated by series of enzymatic steps to produce 
antigens of nearly invariant structure, which has led to the view 
that CD1-presented antigens always have conserved structures. 
The data we present in this paper raise the possibility that chemi-
cally more diverse and mutable antigens composed of amino 
acid sequences encoded in host or pathogen genomes could 
also be antigens for the CD1 system. Interestingly, the viral 
N-terminally acylated proteins HIV Nef and hepatitis B virus 
large surface antigen lose their function if mutated in a way that 
they lose their N-terminal acylation (52, 65). This provides a 
candidate mechanism for coupling of pathogenicity and bind-
ing capacity to the antigen-presenting element.
MATERIALS AND METHODS
Antigens
Lipopeptides were prepared by automated peptide synthesis followed by 
N-acylation of a peptidic backbone with a mixture of fatty acids (C14:0, 
C16:0, C18:0, C18:1, and C20:0; Anaspec Corporation). The unsaturated 
fatty acids were from Sigma-Aldrich, and C18:1 (trans-2-octadecenoic acid) 
was from Matreya. Analogues of lipo-12 were prepared by first synthesizing 
the peptide backbones on a solid-phase peptide synthesizer (ABI 433A; Applied 
Biosystems) using Wang resin (Dana-Farber Cancer Institute Core Facility). 
Lysine and tryptophan were Boc protected, whereas the rest of the amino 
acids were Fmoc protected on their side chains. Finally, the N-stearoyl 
modification (Sigma-Aldrich) of the peptidic backbone was performed, and 
the  lipopeptide  was  released,  dried  under  nitrogen  gas,  resuspended  in 
CHCl3/CH3OH (1:1 vol/vol), and analyzed by HPLC-MS for purity and 
confirmation of the expected mass.
Antigenic compounds and analogues of lipo-12 were fractionated by 
HPLC with a sample-splitting interface to allow for simultaneous preparative 
collection of samples for T cell assays and detection based on ultraviolet light 
absorbance (254 and 280 nm), and ESI-MS with QIT (Finnigan LCQ Ad-
vantage [Thermo Fisher Scientific] or Accurate Mass QTOF [Agilent Tech-
nologies]). A C18 (Vydac) column was used with a gradient elution based on 
solvent A (80:20 vol/vol H2O/CH3CN/H2O with 0.02% TFA and 0.1% 
HCOOH) and solvent B (50:30:20 methanol/acetonitrile/water with 0.02% 
TFA and 0.1% formic acid) using a flow rate of 0.7 ml/min, and a gradient 
starting at 50% B and running to 95% B over 20 min and holding at 95% B 
for the final 10 min. More detailed MSn experiments were performed by 
nano-ESI using borosilicate glass capillaries pulled to a final orifice of 1–2 µm 
and an internal stainless steel electrode. For biological testing, fractions were 
collected at 15-s intervals with an automatic fraction collector, evaporated to 
dryness under nitrogen, and tested for stimulation of T cells. To yield highly 
pure analogues of lipo-12, fractions with the desired m/z value were com-
bined, and dried under nitrogen gas, resuspended in solvent A/solvent B 
(9:1), and again subjected to the described HPLC method to yield samples 
with the highest purity. DDM was purified from M. tuberculosis, as previously 
described (21).
Structural characterization of lipo-12
FTICR MS. The lipo-12 mixture obtained in the initial synthesis was 
subjected to nano–ESI-MS analysis using a home-built qQq FTICR MS 
that they enter early, intermediate, or late compartments of 
the endosomal network (57, 58). Most previous studies have 
emphasized how factors present in late endosomes and lyso-
somes contribute in a positive way to antigen loading and 
recognition by T cells. Specifically, the late endosomal antigen 
presentation pathway facilitates antigen recognition through 
pH-mediated changes in CD1 conformation that increase an-
tigen access to CD1 grooves (9, 44, 59), pH-activated lipid 
transfer proteins (3, 60–62), and pH-activated glycosidases 
that trim antigens (63, 64). Also, in theory, if all CD1 iso-
forms were to use late endosomal pathways, thereby travers-
ing all endosomal compartments, this would enable them to 
encounter the widest possible range of antigens and load them 
under all available conditions.
Contrary to this simple model, CD1a and CD1c do not 
efficiently enter late endosomes and lysosomes, where they 
might take advantage of such specialized lipid loading or pro-
cessing cofactors (32, 34, 35). Instead, CD1a and CD1c pre-
dominantly encounter antigens in the secretory pathway and 
early endosomes and then return to the surface without local-
izing in lysosomes at steady state (32, 34, 35). Furthermore, 
inspection of the sequences of nonhuman CD1 genes sug-
gests that most mammals have large CD1 families containing 
examples of two types of CD1 proteins: those that are and 
those that are not predicted to enter lysosomes. What, then, 
are the potential selective advantages that underlie the evolu-
tionary retention of isoforms that enter early but not late en-
dosomal pathways?
One candidate mechanism that is illustrated in studies 
shown in this paper is that early endosomes might concen-
trate antigens and CD1 proteins for loading, yet expose the 
antigens to chemically and enzymatically mild conditions that 
allow antigens to remain intact during and after loading reac-
tions. Certain antigens, such as lipopeptides and sulfatides, 
may be most efficiently presented if they load at the cell sur-
face (25, 32) or if the complex escapes from the early endo-
somal  environment  to  the  surface  before  entry  into  the 
degradative environment of late endosomes and lysosomes.
More so than the peptide ligands for MHC class II, the li-
gands for CD1 proteins are diverse in their structures and 
chemical reactivity. They can be composed of lipids, pep-
tides, phosphate esters, sulfoesters, and carbohydrates. Known 
antigens range from lipopeptides, which are cleaved by ubiq-
uitous enzymes, to free mycolic acid, which is a chemically 
inert compound that is catabolized by specialized, multistep 
enzymatic systems. As contrasted with models in which CD1 
is  thought  to  sequentially  sample  all  endosomal  compart-
ments, these studies emphasize the distinction between func-
tionally separate early pathways used by CD1a and CD1c, 
and late pathways used more extensively by CD1b and CD1d. 
This dual system could allow presentation of those antigens 
requiring chemically mild loading conditions, and other anti-
gens needing loading factors and pH-driven changes in CD1 
or antigen structure found in late endosomes. We speculate 
that the chemical diversity of CD1-restricted antigens pro-
vides evolutionary pressure for any given mammalian species JEM VOL. 206, June 8, 2009 
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For enzyme-linked immunosorbent spot (ELISPOT), polyvinylidene 
difluoride–backed 96-well plates (Millipore) were coated with 2.5 µg/ml 
anti–IFN- mAb 1-D1K (Mabtech) at 4°C for 16 h and blocked with RPMI 
1640 (Invitrogen) supplemented with 10% fetal bovine serum for 1 h at 
37°C. 2.5 × 104 monocyte DCs were added to wells with serial dilutions of 
lipopeptide antigens and coincubated with 104 T cells for 16 h at 37°C. After 
incubation, the plates were washed six times with PBS containing 0.05% 
Tween 20, and incubated with 0.3 µg/ml of biotinylated anti–IFN- mAb 
7-B6-1-biotin (Mabtech) for 2 h at room temperature. Plates were washed 
again and incubated with streptavidin-conjugated alkaline phosphatase (Sigma 
Aldrich) for 1 h. Individual cytokine-producing cells were identified as spots 
after a 10–20-min reaction with 5-bromo-4-chloro-3-indolyl phosphate and 
nitro blue tetrazolium (SIGMAFAST BCIP/NBT; Sigma Aldrich). An 
ImmunoSpot S5 Macro Analyzer (Cellular Technology Ltd.) was used for 
enumeration of the spots.
Competition assays for recombinant CD1c
Soluble human CD1c fusion proteins covalently linked to human 2-micro-
globulin and to the Fc portion of mouse IgG2a were constructed, produced, 
and purified as previously reported (2). 96-well protein G–coated plates 
(Thermo Fisher Scientific) were incubated with 1.25 µg of CD1c fusion 
protein and 125 ng anti-CD11a (AbD Serotec) per well in PBS, pH 7.4, 
overnight at room temperature. After the plates were washed three times 
with PBS buffer, lipoprotein competitors were sonicated into PBS and added 
to the wells in molar excess. The plates were incubated for 8 h at 37°C before 
adding MPM for additional 18-h incubation at room temperature. The plate 
was then washed three times with 200 µl/well of sterile PBS before adding 
105 CD8-1 T cells in a total volume of 200 µl of T cell medium per well. The 
plates were incubated for 24 h at 37°C, after which culture supernatants were 
collected for IFN- ELISA analysis (Thermo Fisher Scientific). Control ex-
periments demonstrated that CD8-1 was restricted by CD1c, reactive to 
MPM, and not directly reactive to lipopeptides (unpublished data).
Generation of C1R (double) transfectant cell lines  
and confocal microscopy
To create tail swap mutants, human CD1c cDNA was amplified with the 5 
primer VB06 (5-ATCAGCAAACAGCTTTTCTGAGAG-3) and the 3 
primer  VB05  (5-TCATGGGATATTCTGATATGACCGGCGCCT-
CATAAACCATAACACAAGGACTATTAG-3) to generate the CD1cextra/ 
CD1btail mutant, and human CD1b cDNA was amplified with the 5 primer 
VB07 (5-ACCAGCTCTGCCAGTAAGAAGTTGC-3) and the 3 primer 
VB04 (5-TCACAGGATGTCCTGATATGAGCAGTGCTTCTTATAC-
CATAATGCAAGGCATAG-3) to generate the CD1bextra/CD1ctail mutant. 
PCR reactions were performed using High Fidelity Platinum Taq DNA 
polymerase (Invitrogen), and the PCR fragments were cloned into the pEF6-
TOPO TA vector (Invitrogen). The cloned inserts were confirmed by DNA 
sequencing. Transfection of C1R cells expressing either wild-type CD1b or 
CD1c was performed via electroporation, as previously described (31), and 
cells expressing the new chimeric or point mutant CD1 molecules were se-
lected in tissue culture medium containing 10 µg/ml blasticidin.
The transfected C1R cells were attached to cover slides (poly–l-lysine 
coated), fixed with 4% paraformaldehyde, and permeabilized with 0.05% sa-
ponin, as previously described (34). For double staining of CD1b and CD1c, 
the extracellular domain of CD1b was detected with 5 µg/ml of the mAb 
4A7 and revealed with a mouse IgG2a-specific, Alexa Fluor 647–conjugated 
antibody (Invitrogen). The CD1c extracellular domain was detected with 
5 µg/ml of the monoclonal mouse antibody F10/21A3.1 and revealed by the 
mouse IgG1-specific, Alexa Fluor 555–conjugated antibody (Invitrogen). 
The slides were analyzed with a laser scanning confocal microscope (Radi-
ance 2000; Bio-Rad Laboratories), and representative images are shown in 
the figures. For CD1c and LAMP1 double staining, the F10/21A3.1 anti-
body and the anti-LAMP1 H4A3 antibody (BD) were directly conjugated to 
Alexa Fluor 546 and Alexa Fluor 647, respectively (using a labeling kit; Invi-
trogen), as well as the IgG1 isotype control antibody P3. Slides were ana-
lyzed on a confocal laser scanner (TE2000-U C1; Nikon).
instrument (66) fitted with a 7-Tesla actively shielded magnet (Cryomag-
netics Inc.). Accurate masses were measured for the [M+3H]3+, [M+2H]2+, 
and/or [M+H]+ ions, and the products were obtained for selected precur-
sors that were subjected to collision-induced decomposition. The front-
end quadrupoles were controlled using the program LC2Tune 1.5 (MDS 
Analytical Technologies), and the program IonSpec99 (IonSpec Corp.) 
controlled data acquisition in the ion cyclotron resonance cell. Spectra 
were analyzed using the Boston University Data Analysis software, devel-
oped in house.
The lipopeptide sample was diluted 1:40 from its original concentration 
using 1:1 CH3OH/H2O (vol/vol), 1% HCOOH solution, and was sprayed 
using a home-built nanospray source. The solution was loaded into a Kwik-
Fil borosilicate glass capillary tip (1-µm orifice diameter) pulled in house 
with a micropipette puller (P-97 Flaming/Brown; Sutter Instrument Co.). 
Kwik-Fil borosilicate glass capillaries, HPLC-grade methanol, and formic 
acid were obtained from VWR International. All water was filtered using a 
filtration system (Milli-Q Gradient A10; Millipore).
The [M+3H]3+ ions of lipopeptides 1 and 3 and the [M+H]+ ion of li-
popeptide 2 were isolated in the resolving quadrupole and accelerated at 
10 eV into the LINAC quadrupole for collision with N2 gas. Fragment ions 
were accumulated for 1000 ms and transmitted to the ICR cell for detection. 
All spectra were analyzed without apodization and with two zero fills, and 
were  internally  calibrated  based  on  the  m/z  values  calculated  for  the 
[M+3H]3+ ions, the y9 and c6 fragments, and their isotopes.
QIT MS. Compounds of interest were analyzed by isolating the parent 
ions in the QIT MS, collisionally activating them with the helium buffer 
present at low pressure (105 Torr), and, finally, sequentially ejecting the 
product ions from the trap for mass analysis. These experiments were per-
formed both during the HPLC-MS runs with ESI for initial MS/MS analy-
sis and also using offline nano–ESI-MS for more detailed MSnth analysis 
with multiple stages of fragmentation.
Derivation of T cell lines
To  generate  CD1-restricted  T  cells,  primary  human  lymphocytes  from 
HIV+ patients were handled in biosafety level 2+ conditions by stimulation 
with monocyte-derived immature DCs and a synthetic antigen mixture at a 
concentration of 1 µg/ml. 1.25 × 105 T cells and 0.25 × 105 DCs per well 
were cultivated in round-bottom 96-well plates. For the first three rounds of 
stimulation, autologous DCs were used, and heterologous DCs were used 
for subsequent stimulations. Lines were cultivated in T cell medium made by 
supplementing 500 ml RPMI 1640 medium with 50 ml of fetal calf serum 
(Hyclone), penicillin (Invitrogen), streptomycin (Invitrogen), 20 mM Hepes 
(Invitrogen), and 4 ml 1 N NaOH solution. The IL-2 concentration was 
initially 0.1 nM and gradually increased to 1 nM during subsequent rounds 
of stimulation. T cell clones were derived by limiting dilution, using 0.6 × 105 
EBV-transformed and irradiated B cells (10,000 R) and 1.3 × 105 heterolo-
gous irradiated PBMCs (3,300 R) as feeder cells, and 1 µg/ml PHA (Difco) 
in medium containing 2 nM IL-2.
T cell assays
T cell activation was measured by incubating 5 × 104 T cells with 3 × 104 
DCs or CD1-transfected C1R cells. Proliferation was measured after co-
culture for 3 d with antigen, followed by a 6-h pulse of 1 µCi [3H]thymidine 
before harvesting and counting  emissions. Alternatively, supernatants were 
tested for the presence of IL-2 using the HT-2 bioassay. Anti-CD1a (OKT6), 
-CD1b (BCD1b.3), -CD1c (F10/21A3.1), -CD1d (CD1d42), and -IgG1 
control (P3) were used for blocking studies at 20 µg/ml. For studies with 
C1R cells expressing wild-type or chimeric CD1 proteins, a panel of clones 
was tested for surface expression by flow cytometric analysis after staining 
with antibodies to CD1c (F10/21A3.1), or CD1b (BCD1b.3) followed by 
goat anti–mouse PE on nonpermeabilized cells. Clones with equivalent lev-
els of CD1 expression as measured by mean fluorescence intensity (MFI) of 
nonpermeabilized cells within 1d of the assay were used to compare antigen 
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In vitro protease treatment
Pronase is a mixture of endopeptidases and exopeptidases (carboxypeptidases 
and aminopeptidases) that cleave denatured and native proteins down into 
individual amino acids. Proteinase K is an endopeptidase that has a prefer-
ence for cleavage between an aliphatic, aromatic, or hydrophobic and any 
other amino acid; however, it will digest any peptidic bond if added in excess 
and/or allowed to interact over long incubation periods. Pronase and pro-
teinase K were used to digest lipo-12 and DDM in protease buffer (10 mM 
CaCl, 10 mM Hepes buffer, 25 mM ammonium bicarbonate) for 4 h at 
40°C, followed by 10 min of inactivation at 85°C. Mock treatment of anti-
gens was performed in the same buffer and at the same temperatures, but 
without addition of the proteases.
TCR cloning
mRNA was isolated from 106 clonal or polyclonal T cells using an Oligotex 
Direct mRNA kit (QIAGEN), followed by first-strand cDNA synthesis using 
SuperScript RT (Invitrogen). PCR primer sets as described on the Immuno-
genetics website (http://imgt.cines.fr) covering most of the TCR V and V 
families were used to determine the V and V usage. Second-strand cDNA 
synthesis was performed using Escherichia coli DNA ligase (Invitrogen), E. coli 
DNA pol I (Invitrogen), and RNase H (New England Biolabs, Inc.) in E. coli 
ligase buffer (Invitrogen), followed by blunting of the material with T4 poly-
merase and circularization using T4 ligase. Inverse PCR using the constant 
regions of the TCR  and TCR  (C and C) was performed using the 
following primers: CircularCForward, 5-GACCTCATGTCTAGCA-
CAGTTTTG-3; CircularCReverse, 5-GCCCTGCTATGCTGTGT-
GTCT-3; CircularCForward, 5-ACACAGCGACCTCGGGAGGG-3; 
and CircularCReverse, 5-GATGGCCATGGTCAAGAGAAAGGA-3. 
Primers for full-length TCR chains were: FLTRBV12-3, 5-GCCATG-
GACTCCTGGACCTTCTGCT-3;  and  FLTRAV25,  5-GGGAGAT-
GCTACTCATCACATCAATGTTG-3. PCR products were cut from an 
agarose gel, purified, and ligated in a Topo4blunt vector that was used to 
transform one-shot Top10 cells (Invitrogen). Vector DNA of single colonies 
was sequenced by Baseclear.
Online supplemental material
Fig. S1 shows T cell recognition of synthetic lipopeptides mimicking acyl-
ated proteins from mammalian cells or viruses. Fig. S2 depicts the amino acid 
sequence of the 1A3 TCR. Fig. S3 shows MS2 data supporting the structure 
of lipopeptides 1 and 2. Fig. S4 depicts the synthesis and analysis of 12-mer 
lipopeptides. Fig. S5 shows the synthesis and analysis of tryptophan point 
mutant at position 7. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20082480/DC1.
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